These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 36895328)

  • 21. Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI 2536.
    Gleixner KV; Ferenc V; Peter B; Gruze A; Meyer RA; Hadzijusufovic E; Cerny-Reiterer S; Mayerhofer M; Pickl WF; Sillaber C; Valent P
    Cancer Res; 2010 Feb; 70(4):1513-23. PubMed ID: 20145140
    [TBL] [Abstract][Full Text] [Related]  

  • 22. EPS8 regulates proliferation, apoptosis and chemosensitivity in BCR-ABL positive cells via the BCR-ABL/PI3K/AKT/mTOR pathway.
    Huang R; Liu H; Chen Y; He Y; Kang Q; Tu S; He Y; Zhou X; Wang L; Yang J; Wu A; Li Y
    Oncol Rep; 2018 Jan; 39(1):119-128. PubMed ID: 29192326
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The novel Aurora A kinase inhibitor MLN8237 is active in resistant chronic myeloid leukaemia and significantly increases the efficacy of nilotinib.
    Kelly KR; Ecsedy J; Medina E; Mahalingam D; Padmanabhan S; Nawrocki ST; Giles FJ; Carew JS
    J Cell Mol Med; 2011 Oct; 15(10):2057-70. PubMed ID: 21091633
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Aclacinomycin A sensitizes K562 chronic myeloid leukemia cells to imatinib through p38MAPK-mediated erythroid differentiation.
    Lee YL; Chen CW; Liu FH; Huang YW; Huang HM
    PLoS One; 2013; 8(4):e61939. PubMed ID: 23613979
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Apicidin potentiates the imatinib-induced apoptosis of Bcr-Abl-positive human leukaemia cells by enhancing the activation of mitochondria-dependent caspase cascades.
    Kim JS; Jeung HK; Cheong JW; Maeng H; Lee ST; Hahn JS; Ko YW; Min YH
    Br J Haematol; 2004 Jan; 124(2):166-78. PubMed ID: 14687026
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Simvastatin potentiates the cell-killing activity of imatinib in imatinib-resistant chronic myeloid leukemia cells mainly through PI3K/AKT pathway attenuation and Myc downregulation.
    Ding L; Chen Q; Chen K; Jiang Y; Li G; Chen Q; Bai D; Gao D; Deng M; Zhang H; Xu B
    Eur J Pharmacol; 2021 Dec; 913():174633. PubMed ID: 34843676
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alvespimycin Inhibits Heat Shock Protein 90 and Overcomes Imatinib Resistance in Chronic Myeloid Leukemia Cell Lines.
    Alves R; Santos D; Jorge J; Gonçalves AC; Catarino S; Girão H; Melo JB; Sarmento-Ribeiro AB
    Molecules; 2023 Jan; 28(3):. PubMed ID: 36770876
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discovery of a highly potent kinase inhibitor capable of overcoming multiple imatinib-resistant ABL mutants for chronic myeloid leukemia (CML).
    Lu T; Cao J; Zou F; Li X; Wang A; Wang W; Liang H; Liu Q; Hu C; Chen C; Hu Z; Wang W; Li L; Ge J; Shen Y; Ren T; Liu J; Xia R; Liu Q
    Eur J Pharmacol; 2021 Apr; 897():173944. PubMed ID: 33581133
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Endoplasmic reticulum stress-mediated apoptosis in imatinib-resistant leukemic K562-r cells triggered by AMN107 combined with arsenic trioxide.
    Xia Y; Fang H; Zhang J; Du Y
    Exp Biol Med (Maywood); 2013 Aug; 238(8):932-42. PubMed ID: 23883479
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Everolimus in combination with Imatinib overcomes resistance in Chronic myeloid leukaemia.
    Alves R; Gonçalves AC; Jorge J; Alves J; Alves da Silva A; Freitas-Tavares P; Nascimento Costa JM; Almeida AM; Sarmento-Ribeiro AB
    Med Oncol; 2019 Feb; 36(3):30. PubMed ID: 30796703
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Correction of Bcl-x splicing improves responses to imatinib in chronic myeloid leukaemia cells and mouse models.
    Zhang J; Wang Y; Li SQ; Fang L; Wang XZ; Li J; Zhang HB; Huang B; Xu YM; Yang WM; Lin J; Min QH; Liao ZH; Wu Y; Liu J
    Br J Haematol; 2020 Jun; 189(6):1141-1150. PubMed ID: 32189339
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Knock-down of CIAPIN1 sensitizes K562 chronic myeloid leukemia cells to Imatinib by regulation of cell cycle and apoptosis-associated members via NF-κB and ERK5 signaling pathway.
    Wang J; Li Q; Wang C; Xiong Q; Lin Y; Sun Q; Jin H; Yang F; Ren X; Pang T
    Biochem Pharmacol; 2016 Jan; 99():132-45. PubMed ID: 26679828
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Proteomics analysis reveals the correlation of programmed ROS-autophagy loop and dysregulated G1/S checkpoint with imatinib resistance in chronic myeloid leukemia cells.
    Xu X; Yin S; Ren Y; Hu C; Zhang A; Lin Y
    Proteomics; 2022 Jan; 22(1-2):e2100094. PubMed ID: 34564948
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ribavirin Inhibits the Activity of mTOR/eIF4E, ERK/Mnk1/eIF4E Signaling Pathway and Synergizes with Tyrosine Kinase Inhibitor Imatinib to Impair Bcr-Abl Mediated Proliferation and Apoptosis in Ph+ Leukemia.
    Shi F; Len Y; Gong Y; Shi R; Yang X; Naren D; Yan T
    PLoS One; 2015; 10(8):e0136746. PubMed ID: 26317515
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of deferasirox, an iron chelator, to overcome imatinib resistance of chronic myeloid leukemia cells.
    Kim DS; Na YJ; Kang MH; Yoon SY; Choi CW
    Korean J Intern Med; 2016 Mar; 31(2):357-66. PubMed ID: 26874514
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biochemical and chemical characterization of Cynara cardunculus L. extract and its potential use as co-adjuvant therapy of chronic myeloid leukemia.
    Russo A; Perri M; Cione E; Di Gioia ML; Nardi M; Cristina Caroleo M
    J Ethnopharmacol; 2017 Apr; 202():184-191. PubMed ID: 28323047
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Epigenetic down-regulation of BIM expression is associated with reduced optimal responses to imatinib treatment in chronic myeloid leukaemia.
    San José-Eneriz E; Agirre X; Jiménez-Velasco A; Cordeu L; Martín V; Arqueros V; Gárate L; Fresquet V; Cervantes F; Martínez-Climent JA; Heiniger A; Torres A; Prósper F; Roman-Gomez J
    Eur J Cancer; 2009 Jul; 45(10):1877-89. PubMed ID: 19403302
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Blockade of the interaction between Bcr-Abl and PTB1B by small molecule SBF-1 to overcome imatinib-resistance of chronic myeloid leukemia cells.
    Elgehama A; Chen W; Pang J; Mi S; Li J; Guo W; Wang X; Gao J; Yu B; Shen Y; Xu Q
    Cancer Lett; 2016 Mar; 372(1):82-8. PubMed ID: 26721204
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cryptotanshinone acts synergistically with imatinib to induce apoptosis of human chronic myeloid leukemia cells.
    Ge Y; Yang B; Xu X; Dai Q; Chen Z; Cheng R
    Leuk Lymphoma; 2015 Mar; 56(3):730-8. PubMed ID: 24884318
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cryptotanshinone enhances the efficacy of Bcr-Abl tyrosine kinase inhibitors via inhibiting STAT3 and eIF4E signalling pathways in chronic myeloid leukaemia.
    Cheng R; Huang Y; Fang Y; Wang Q; Yan M; Ge Y
    Pharm Biol; 2021 Dec; 59(1):893-903. PubMed ID: 34214017
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.